<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Entry into the cell cycle is governed by cyclins, cyclin-dependent kinases (CDKs) and CDK-inhibitors (CDKIs) </plain></SENT>
<SENT sid="1" pm="."><plain>The p53-regulated inhibitor of CDKs (PIC1) is a universal CDKI whose gene expression is directly induced by the p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor protein </plain></SENT>
<SENT sid="2" pm="."><plain>Reverse transcription and polymerase chain reaction revealed strong PIC1 gene expression in control MRC-5 human embryo lung cells, but relatively weaker bands in A549 <z:mp ids='MP_0008714'>lung carcinoma</z:mp>; Hep3B, Mahlavu, PLC/PRF/5 <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>; SiHa, CaSki, HeLa cervical <z:mp ids='MP_0002038'>carcinoma</z:mp>; T24 <z:hpo ids='HP_0002862'>bladder carcinoma</z:hpo>; MCF7 <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo>; Raji Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; HT-1080 <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo>; and G-401 Wilms' <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>These data are consistent with other results obtained by Northern and Western blot and immunoprecipitation techniques, indicating diminished PIC1 expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells especially those harboring mutated p53, or <z:e sem="disease" ids="C0850011,C0850009" disease_type="Disease or Syndrome" abbrv="">human papillomavirus</z:e> E6 oncoproteins which abrogate p53 activity </plain></SENT>
<SENT sid="4" pm="."><plain>PIC1 gene expression was absent in the Molt-4 T-lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell line with a previously documented alternatively-spliced p53 transcript translating into p53 protein truncated at the carboxyl terminus </plain></SENT>
<SENT sid="5" pm="."><plain>It is proposed that this aberrant p53 interferes with the binding of <z:mp ids='MP_0002169'>wild-type</z:mp> p53 and other transcription factors to the PIC1 promoter thereby abolishing PIC1 gene expression </plain></SENT>
<SENT sid="6" pm="."><plain>This Molt-4 cell line could serve as a useful experimental system for studying the interaction between p53 and other cellular factors with the PIC1 gene </plain></SENT>
<SENT sid="7" pm="."><plain>Single-strand conformation polymorphism and direct cycle DNA sequencing analyses demonstrated a PIC1 variant (with an AGC to AGA substitution at codon 31 culminating in a serine to arginine replacement) in Mahlavu, PLC/PRF/5, SiHa, A549 and Raji cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>The higher proportion of the PIC1 variant in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines (5/13 or 38%) compared with <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (14%), coupled with differences between the predicted secondary structures of the <z:mpath ids='MPATH_458'>normal</z:mpath> and variant PIC1 proteins merit further investigations to elucidate the biological significance of this variant </plain></SENT>
</text></document>